Urethral Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Urethral Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Urethral cancer is a condition in which cancerous (malignant) cells form tumors in the tissues of urethra. Urethra is the tube through which urine flows out of the bladder. A history of bladder cancer can affect the risk of urethral cancer and it occurs more often in men than in women. The symptoms include blood in urine, discharge or bleeding from the urethra etc. Diagnosis involves examination, imaging tests (such as CT or MRI scans), urethroscopy, and a biopsy to confirm the presence of cancer cells.
The Urethral Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Urethral Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urethral Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Urethral Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 44 molecules, with 42 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Urethral Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Urethral Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Urethral Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akamis Bio LtdAravive Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Bristol-Myers Squibb Co
Checkpoint Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Ectin Research AB
Eli Lilly and Co
Evaxion Biotech A/S
Evopoint Bioscience Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Gilead Sciences Inc
GlyTherix Ltd
Hangzhou DAC Biotech Co Ltd
Hengrui Yuanzheng Biotechnology Co Ltd
IO Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
MedPacto Inc
Merck & Co Inc
Merck KGaA
Minghui Pharmaceutical (Shanghai) Co Ltd
NeoTX Therapeutics Ltd
Pfizer Inc
Puretech Health Plc
RemeGen Co Ltd
Seagen Inc
Shandong New Time Pharmaceutical Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Miracogen Inc
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Geno-Immune Medical Institute
Shionogi & Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Urethral Cancer reports